|
مقاله
|
Abstract
|
|
|
|
Title:
|
The Effect of the Fasudil, a Rho-Associated Protein Kinase Inhibitor, on Intraocular Pressure
|
|
Author(s):
|
Mohammad Pakravan, MD; Afsaneh Naderi Beni1, MD; Elham Ghahari, MD; Reyhaneh Varshochian, MD; Shahin Yazdani, MD; Hamid Ahmadieh,MD; Hamed Esfandiari, MD
|
|
Presentation Type:
|
Oral
|
|
Subject:
|
Glaucoma
|
|
Others:
|
|
|
Presenting Author:
|
|
|
Name:
|
Mohammad Pakravan
|
|
Affiliation :(optional)
|
Ophthalmic Research Center, Ophthalmology Department, Labbafinejad Medical Center
|
|
E mail:
|
mohpakravan@icloud.com
|
|
Phone:
|
98-21-22560032
|
|
Mobile:
|
98-9121433478
|
|
|
|
|
Purpose:
|
To investigate the effects of topical administration of a selective Rho-associated kinase (ROCK) inhibitor, Fasudil 0.5% and 1.2% in glaucomatous patients.
|
|
Methods:
|
In this interventional case series 4 eyes of 4 patients with unilateral end-stage primary open angle glaucoma (POAG) and no light perception vision were assigned to receive topical fasudil 0.5 and 1.2% ophthalmic solution. Dosing was twice daily for 8 weeks. At weeks 1, 2, 3, 4 and 8, ocular examinations were performed and IOP was measured. Ocular symptoms and adverse events were evaluated.
|
|
Results:
|
The mean baseline IOP was 52 mm Hg. The mean IOP reductions of the last visit from baseline were -7.75 mm Hg at 2 hours, and -8.75mmHg at 4 hours. All 2 concentrations of fasudil produced statistically and clinically significant reductions in mean IOP with peak effects occurring 2 to 4 hours after dosing. The largest IOP reductions were produced by 1.2% fasudil (up to 12 mm Hg; 21.1%). Conjunctival hyperemia was found in 1 patient with 1.2% fasudil.
Conclusions: Topical administration of fasudil in patients with end–stage POAG caused a reduction in IOP and was well tolerated. ROCK inhibitors could be a candidate for glaucoma therapy in future.
|
|
Conclusion:
|
Fasudil, Rho-Associated Protein Kinase Inhibitor; intraocular pressure; glaucoma
|
|
Attachment:
|
|
|